NCT00611858View on ClinicalTrials.gov

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2012

Study Completion Date

September 30, 2016

Conditions
Rectal Cancer
Interventions
DRUG

Cetuximab

DRUG

5-Fluorouracil

RADIATION

Radiation

Trial Locations (4)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

Unknown

South Shore Hospital, Weymouth

Vanderbilt Medical Center, Nashville

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00611858 - Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter